Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

501
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Amyloid Fibrils03:03

Amyloid Fibrils

9.3K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Neural Regulation01:37

Neural Regulation

39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
  1. Home
  3. Α-synuclein Pathology In Synucleinopathies: Mechanisms, Biomarkers, And Therapeutic Challenges.
  1. Home
  3. Α-synuclein Pathology In Synucleinopathies: Mechanisms, Biomarkers, And Therapeutic Challenges.

Related Experiment Video

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.5K

α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.

Oscar Arias-Carrión1,2, Magdalena Guerra-Crespo3, Francisco J Padilla-Godínez3,4

  • 1Experimental Neurology, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City 14389, Mexico.

International Journal of Molecular Sciences
|June 13, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Parkinson's disease and related synucleinopathies involve alpha-synuclein (aSyn) protein aggregation. Understanding aSyn biology, propagation, and systemic influences is key for developing new biomarkers and treatments.

Keywords:
Parkinson’s diseasealpha-synucleinbiomarkersneurodegenerationprotein aggregationsynucleinopathies

More Related Videos

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.7K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.3K

Related Experiment Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.5K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.7K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.3K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Synucleinopathies, including Parkinson's disease, are defined by alpha-synuclein (aSyn) protein aggregation in brain cells.
  • This aggregation leads to cellular dysfunction and neurodegeneration, causing various neurological disorders.

Purpose of the Study:

  • To synthesize current knowledge on alpha-synuclein (aSyn) biology, aggregation, and propagation mechanisms.
  • To explore the systemic influences, including immune responses and the gut microbiome, on aSyn pathology.
  • To review advances in biomarker development and therapeutic strategies for synucleinopathies.

Main Methods:

  • Literature review of aSyn biology, aggregation, and propagation.
  • Analysis of cellular and systemic factors influencing aSyn pathology.
  • Evaluation of current and emerging diagnostic biomarkers and therapeutic approaches.

    • Main Results:

    • aSyn aggregates exhibit diverse structures and strain-like properties, potentially propagating via prion-like mechanisms.
    • Dysfunctional protein clearance pathways and post-translational modifications enhance aSyn accumulation and toxicity.
    • Peripheral factors, such as gut microbiome alterations and immune responses, significantly modulate central neurodegeneration.

    Conclusions:

    • Reliable biomarkers for early diagnosis and disease monitoring are crucial for developing effective treatments for synucleinopathies.
    • Interdisciplinary approaches integrating genetic, epigenetic, and environmental factors are needed to model and treat these complex diseases.
    • Further research into aSyn biology and its systemic interactions is essential for advancing therapeutic interventions.